Shanghai Qiran Biotechnology

Qiran Bio is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing innovative gene therapies using advanced AAV delivery systems. The company utilizes a proprietary platform for AAV capsid engineering and high-throughput screening to identify vectors with improved tissue tropism and reduced immunogenicity. Its lead program, QR001, is an AAV-based gene therapy targeting neovascular age-related macular degeneration (nAMD). Qiran Bio's broader pipeline addresses unmet needs in ophthalmology, metabolic disorders, and other rare diseases. The company is backed by prominent venture capital firms and maintains state-of-the-art R&D facilities in Shanghai.